Table 3.

The effects of a 6-week administration of 13-cis-RA (1 mg/kg/day, i.p.) and a 1-week administration of BLEB (125 nmol/day, intra-arterial) on mean blood pressure (MBP, mmHg), systolic blood pressure (SBP, mmHg), diastolic blood pressure (DBP, mmHg), heart rate (HR, beats/min), and urine production (UP, ml/day)

Treatment	MBP (mmHg)	SBP (mmHg)	DBP (mmHg)	HR (beats/min)	UP (ml/day)
Control	105.2 ± 3.22	111.2 ± 4.86	80.33 ± 2.25	253.4 ± 4.96	15.8 ± 0.69
13-cis-RA	114.0 ± 1.98	120.6 ± 3.75	87.60 ± 2.46	264.1 ± 4.10	17.5 ± 0.74
BLEB	109.3 ± 6.73	122.7 ± 4.81	85.80 ± 2.42	250.9 ± 5.60	17.4 ± 0.70
13-cis-RA + BLEB	108.9 ± 5.04	124.3 ± 3.91	84.00 ± 2.65	257.8 ± 4.65	15.6 ± 0.68

Data were analyzed by the two-way analysis of variance (two-way ANOVA), n = 15 in each group. MBP: 13-cis-RA effect [F(1,56) = 0.8283, p = 0.3667], BLEB effect [F(1,56) = 0.01174, p = 0.9141), 13-cis-RA × BLEB interaction [F(1,56) = 0.9936, p = 0.3231). SBP: 13-cis-RA effect [F(1,56) = 1.587, p = 0.2130], BLEB effect [F(1,56) = 3.030, p = 0.0872), 13-cis-RA × BLEB interaction [F(1,56) = 0.7979, p = 0.3755). DBP: 13-cis-RA effect [F(1,56) = 1.240, p = 0.2702], BLEB effect [F(1,56) = 0.1449, p = 0.7049), 13-cis-RA × BLEB interaction [F(1,56) = 3.410, p = 0.0701). HR: 13-cis-RA effect [F(1,56) = 3.276, p = 0.0756], BLEB effect [F(1,56) = 0.8191, p = 0.3693), 13-cis-RA × BLEB interaction [F(1,56) = 0.1527, p = 0.6974). UP: 13-cis-RA effect [F(1,56) = 6.243, p = 0.9607], BLEB effect [F(1,56) = 6.243, p = 0.8935), 13-cis-RA × BLEB interaction [F(1,56) = 6.243, p = 0.0154)